Molecule intelOpportunity: ModerateEssentialCrowded market

Clindamycin

156 brands · 73 companies · product forms

ATC: D10AF01, G01AA10, J01FF01

Opportunity snapshot

Launch attractiveness
35
Market saturation
100
Price room
100
Regulatory risk
0
156
brands
73
companies
Rs 351.79
median price
94
price points
13.14x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 9%

Price room

Across observed sources and strengths
CheapestRs 61.8
MedianRs 351.79
Most expensiveRs 812.25
Spread13.14×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 13.14x across 94 trusted points (Rs 61.8-812.25). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Clindamycin — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(0) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

73 canonical companies and 156 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 13.14x across 94 trusted points (Rs 61.8-812.25). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.